Cargando…
ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did
Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251456/ https://www.ncbi.nlm.nih.gov/pubmed/34230747 http://dx.doi.org/10.1111/jbfa.12523 |
_version_ | 1783717097300295680 |
---|---|
author | Demers, Elizabeth Hendrikse, Jurian Joos, Philip Lev, Baruch |
author_facet | Demers, Elizabeth Hendrikse, Jurian Joos, Philip Lev, Baruch |
author_sort | Demers, Elizabeth |
collection | PubMed |
description | Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures of performance, financial position and intangibles investments have been controlled for, ESG offers no such positive explanatory power for returns during the COVID crisis. Specifically, ESG is insignificant in fully specified returns regressions for each of the Q1 2020 COVID market crisis period and for the full COVID year of 2020. By contrast, a measure of the firm's stock of investments in internally generated intangible assets is an economically and statistically significant positive determinant of returns during each of the Q1 market implosion and full 2020 COVID year periods. Our results are robust to alternative measures of returns, as well as for using Refinitiv, Refinitiv II and MSCI data to capture ESG performance. We conclude that ESG did not immunize stocks during the COVID‐19 crisis, but those investments in intangible assets did. |
format | Online Article Text |
id | pubmed-8251456 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82514562021-07-02 ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did Demers, Elizabeth Hendrikse, Jurian Joos, Philip Lev, Baruch J Bus Finance Account Articles Environmental, social and governance (“ESG”) scores have been widely touted as indicators of share price resilience during the COVID‐19 crisis. Contrary to this conventional wisdom, we present robust evidence that once industry affiliation, market‐based measures of risk and accounting‐based measures of performance, financial position and intangibles investments have been controlled for, ESG offers no such positive explanatory power for returns during the COVID crisis. Specifically, ESG is insignificant in fully specified returns regressions for each of the Q1 2020 COVID market crisis period and for the full COVID year of 2020. By contrast, a measure of the firm's stock of investments in internally generated intangible assets is an economically and statistically significant positive determinant of returns during each of the Q1 market implosion and full 2020 COVID year periods. Our results are robust to alternative measures of returns, as well as for using Refinitiv, Refinitiv II and MSCI data to capture ESG performance. We conclude that ESG did not immunize stocks during the COVID‐19 crisis, but those investments in intangible assets did. John Wiley and Sons Inc. 2021-04-08 2021 /pmc/articles/PMC8251456/ /pubmed/34230747 http://dx.doi.org/10.1111/jbfa.12523 Text en © 2021 The Authors. Journal of Business Finance & Accounting published by John Wiley & Sons Ltd https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Articles Demers, Elizabeth Hendrikse, Jurian Joos, Philip Lev, Baruch ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title | ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title_full | ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title_fullStr | ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title_full_unstemmed | ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title_short | ESG did not immunize stocks during the COVID‐19 crisis, but investments in intangible assets did |
title_sort | esg did not immunize stocks during the covid‐19 crisis, but investments in intangible assets did |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251456/ https://www.ncbi.nlm.nih.gov/pubmed/34230747 http://dx.doi.org/10.1111/jbfa.12523 |
work_keys_str_mv | AT demerselizabeth esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid AT hendriksejurian esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid AT joosphilip esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid AT levbaruch esgdidnotimmunizestocksduringthecovid19crisisbutinvestmentsinintangibleassetsdid |